ID2 and central nervous system cancer: Other studies support the increase in ID1 and ID2 expression levels in H3K27-altered gliomas, either through mutations in ACVR1 and the upregulation of pSMAD1/5 in H3.1-altered gliomas [14,27] or through other mechanisms in H3.3-altered gliomas [14].